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Delivery of Triazolam and Baclofen by Gastrostomy Tubes (86 pp.) 
Director: Todd G. Cochran:
Delivery of potent drugs by gastrostomy tubes to critically ill 
patients has become a major concern in recent years because of the 
increased number of reported drug-plastic interactions. Delivery of two 
potent drugs, triazolam a hypnotic and sedative and baclofen a skeletal 
muscle relaxant were studied in teflon coated silicon rubber Foley 
catheters and in Ross flexiflo replacement G-tubes. Sorption studies 
were conducted under static (equilibrium), dynamic (flow) and clinical 
simulation conditions in Foley catheters for triazolam. Sorption, 
dynamic and clinical simulation studies were conducted in Foley 
catheters for baclofen and in Ross tubes for both drugs. The variability 
in drug loss to different Foley catheters also was studied.
Drug loss (20-70%) to delivery tubes was evident for triazolam in both 
the tubes. No loss was observed for baclofen in either tube. Drug loss 
to delivery tubing was related to the chemical nature, water solubility 
and physicochemical properties of the drugs and tube materials.
Sorption of triazolam to the Foley and Ross tubes was observed for up 
to 72 hours. Equilibrium conditions were not reached in this period and 
drug loss was irreversible in both tubes. Drug loss was dependent upon 
concentration of the test solution, amount of drug presented to the tube 
surface, time and flow rate. Drug loss was greater at higher 
concentrations, longer time of contact, larger volumes (and amounts) of 
drug solution and at slower flow rates. The observed drug loss was 
consistent with diffusion controlled absorption of the drug into the 
tube, and was attributed to interaction between drug and the lipophilic 
tube materials. Slow equilibration and irreversibility of drug loss in 
repeated trials in the same tube indicate a multi-layer formation or 
possibly chemisorption even before drug diffused into the tube matrix. 
Greater inter-tube variability than intra-tube variability in the extent 
of drug sorption was observed. This variability in drug sorption among 
different Foley catheters was attributed to differences in tube 
construction and physicochemical properties. It was observed that 
materials leached from the Foley catheters into the drug solutions 
stored in these tubes.
Sorption problems, low therapeutic dose and high ratio of dose related 
complications with triazolam necessitate further investigation of 
absorption, distribution and elimination kinetics of this drug in tube 
fed patients. These studies can be extended to other drugs and other 
types of delivery tubes.
ii
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INTRODUCTION
Enteral feeding
In certain disease conditions, patients cannot swallow 
food or medicines by mouth. In those situations patients are 
fed by the parenteral route or by enteral feeding tubes (1- 
24). When parenteral feeding is not necessitated and 
patients have to be fed for longer periods, enteral tube 
feeding is recommended. Situations where tube feeding is 
necessary include anorexia resulting from trauma, burns, 
cerebrovascular accidents, or disease (1,6-10). Other 
conditions such as mechanical impediments to eating, 
depression or coma may also prevent patients from oral 
intake (5).
The method of feeding depends on the status of the 
gastrointestinal tract and the quantity of calories required 
(2). Enteral feeding promotes more efficient utilization of 
nutrients and better preservation of intestinal integrity 
than does parenteral administration (11). The gut is the 
preferred route when it is functioning and accessible. 
Enteral alimentation is generally safer and more economical 
than parenteral alimentation and, when tolerated, is the 
preferred route of nutrient administration for patients 
requiring intensive nutritional support (4).
There is evidence both theoretical and practical 
suggesting that enteral feeding is superior to parenteral 
alimentation with regard to substrate utilization (1).
Unlike parenteral feeding, which exposes the tissues to 
unmetabolized nutrients, enteral alimentation preserves the 
physiologic sequence of nutrient absorption, metabolism and 
utilization, prior to delivery to the peripheral circulation 
(19) .
Tube enterostomy refers to the operative placement of a 
tube or catheter into any segment of the gastrointestinal 
tract, from the pharynx to the colon (26). The surgical 
placement of a tube or a catheter into the gastrointestinal 
tract for nutrient delivery is indicated when the
1
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nasoenteric route is unavailable or when long term enteral 
alimentation of more than four weeks is anticipated (1). 
Enterostomy is required in situations such as tumors of the 
esophagus, and stomach or benign conditions such as 
strictures or collagen-vascular diseases (1). In such 
situations, the operative insertion of a feeding tube distal 
to the obstruction will allow the normal process of 
intestinal digestion and absorption to continue. Even if the 
upper gastrointestinal tract is mechanically intact, central 
neurologic disorders (multiple sclerosis, cerebral vascular 
accidents, infection or tumor) or primary muscular 
disfunction may interfere with swallowing and reduce or 
prevent oral intake (5,6,8,9,10). If the condition appears 
to be chronic, a tube enterostomy offers a more secure, 
manageable access site for enteral nutrition.
Gastrostomy, in which the tube is surgically implanted 
between the stomach and the abdominal surface, is the most 
commonly used method of enterostomy (26). This technique is 
widely accepted because of its wide applications, limited 
side effects, greater reservoir capacity, economy and high 
patient compliance. Gastrostomy is particularly useful for 
prolonged or permanent feeding (36). Gastrostomy requires a 
stomach uninvolved by primary disease, normal gastric and 
duodenal emptying, no significant esophageal reflux, and 
intact gag reflexes (26). Utilization of the stomach is 
important because of its reservoir capacity which allows 
intermittent bolus feeding without the need for a continuous 
pump infusion.
The development of percutaneous endoscopic gastrostomy 
(PEG), in 1980 by Gauderer and Ponsky opened a new era in 
the field of enteral feeding (39). In PEG, flexible 
endoscopes are placed in 15-20 minutes without general 
anesthesia. The procedure involves the placement of a 
gastrostomy catheter through a guide needle and sheath, PEG 
is a less expensive, non surgical procedure with fewer 
complications. Because of its ease and the rapidity of the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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procedure, low procedure related mortality, very few major 
and minor complications, and easier maintenance and 
replacement, PEG has become the procedure of choice in 
recent years (37). PEG is receiving wide acceptance 
including paediatric patients, debilitated neurologic cases, 
and elderly patients, who usually have more complications 
with anaesthesia and surgery (38).
Gastrostomy tubes (G-tubes) made of rubber and latex 
are commonly used for long term delivery of feeding. There 
are number of feeding tubes available. The large-bore 
gastrostomy tube is more advantageous for delivery of 
medication and high-viscosity nutrient formulae. Most of 
the feeding tubes for different routes of administration are 
made of polyurethane, polyvinylchloride, silicone, silicone 
rubber or polyethylene (28). Softer, more pliable enteral 
feeding tubes made of silicone and polyurethane are less 
reactive with body tissue, and have been widely used in 
recent years (40). These tubes are divided into nasoenteral 
feeding (naso-gastric, naso-duodenal and naso-jejunal) and 
enteral feeding (jejunostomy, gastrostomy, ileostomy, and 
colostomy) categories (1,28). The only differences among 
these three types of tubes are their dimensions (length, 
diameter). Gastrostomy tubes are shorter (76.2 cm or 30 in) 
and range from 5 French to 24 French in diameter (measured 
in French size) (28).
Administration of medication bv enteral feeding tubes
Drugs are most commonly administered through the oral 
route, where the drug is prepared (disintegration, 
dissolution) by the stomach and delivered to the absorptive 
sites of the small intestine. Patients who are being fed by 
enteral feeding tubes frequently are given medication via 
the feeding tube, either with the nutrient formula or 
separately. When the entry route is altered by the placement 
of enteral feeding tubes, the pharmacologic agent and its 
mode of delivery are often modified depending on the size
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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and placement of tubes and also on the type of dosage form 
(1). Large drug particles (crushed tablets, granules, 
powders, suspensions) are administered along with bolus 
enteral feedings by large-bore, nasogastric or gastrostomy 
tubes. If the tubes are placed beyond the stomach where 
disintegration and dissolution is a problem drugs must be in 
liquid form with low viscosity and the tubes should be 
flushed with water after each dose. Studies indicate that 
drugs generally are better absorbed in the fasted state than 
in the fed. So the most suitable time for drug 
administration by feeding tubes is one hour before or two 
hours after a meal (62).
The rate of absorption of food or drugs delivered into 
the stomach by oral or tube feeding is dependent upon the 
gastric emptying rate (GER). There are several factors which 
directly or indirectly affect GER. Physiologic factors 
included disease states such as ulcer, severe trauma, 
myocardial infarction and gastric carcinoma (1). The GER can 
be delayed by drugs (e.g. belladonna alkaloids, 
chlorpromazine, amitriptyline.), or increased by drugs (e.g. 
metaclopramide, anticholinergic, reserpine) (1). Food can 
also effect the absorption of drugs, either to decrease 
absorption (e.g ampicillin, tetracycline and phénobarbital), 
or to increase absorption (e.g propranolol, metoprolol and 
griseofulvin) (1). Since absorption is slow from the 
stomach, faster gastric emptying leads to rapid absorption 
of drugs and quicker onset of action. Therefore, in tube fed 
patients one must evaluate carefully, factors affecting GER, 
type of dosage forms, particle size, volume, rate of feeding 
and other factors such as compatibility with food and other 
drugs.
It is recommended that a commercial liquid dosage form 
should always be used when it is available. Solid dosage 
forms should be used only when liquid products are not 
available. When a liquid dosage form of a drug is not 
available one must prepare a solution or a suspension from
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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solid oral dosage forms. While reprocessing solid dosage 
forms into a liquid form for enteral administration, 
problems such as non-uniformity of particle size, choice of 
an improper suspending agent and production of an unstable 
drug product must be carefully viewed. Knowledge of 
interfacial phenomenon, colloidal dispersion and 
flocculation is very important in making pharmaceutically 
viable liquid formulations (134). At no time, should enteric 
coated or slow released drug formulations or drugs 
contraindicated for oral use be administered by feeding 
tubes.
Problems of drug administration bv enteral feeding tubes
Enteral feeding tubes are generally made of 
polyurethane, polyethylene, polyvinyl chloride (PVC), 
silicon, or silicon rubber. They represent a chamber with 
possible sorptive capacity. Some recently conducted studies 
reported that problems may occur with drug delivery through 
feeding tubes (81-111).
One of the potential problems of administering drugs 
through G-tubes is binding interaction between the drugs and 
the non-polar materials of the tubes which results in 
decreased delivery of drugs to the patients (80). Drugs with 
low water solubility and high affinity for lipids present 
the greatest potential for sorptive loss to plastic tubing.
Administration of different drugs, nutrients and other 
fluids concurrently or within a short time span is likely to 
increase the potential for problems of interactions with 
each other or with the tube material (46-80). A major 
concern is the delivery of drugs by G-tubes with and without 
food. Although there is very little data available regarding 
the delivery of drugs by gastrostomy or other types enteral 
feeding tubes, there are literature reports showing loss of 
drugs to intravenous tubing and other materials which are 
directly comparable to enteral feeding tubes (81-111).
The complications involved in the delivery of drugs by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
polymeric materials are well documented. Insulin is reported 
to be adsorbed to glass containers, PVC surfaces, IV tubing, 
polyolefin infusion bottles and plastic containers (81- 
84,87-89). Vitamin A is reported to be sorbed to polyvinyl, 
polyolefin IV tubing and plastic IV infusion bags 
(85,86,94,95,97), Binding of drugs to plastics appears to be 
a major problem when polymeric delivery devices are used to 
administer drugs (90,96,101). Interaction of drugs with 
plastics has been well documented for diazepam and 
nitroglycerin (102-111). Drugs are also reported to be 
interactive with food and electrolytes (46-80). Binding of 
drugs to caseinate salts, calcium and other electrolytes has 
been reported (66,72). Drug interaction with protein 
nutrient formulas is also a problem in the delivery of drugs 
by feeding tubes (78-80), Stability problems for drugs in 
total nutrient admixtures for gentamicin, phenytoin, 
carbamazepine and warfarin have been evaluated 
(46,48,50,55). Leaching of plasticizer into the solution is 
well documented (111-132). Toxicity from leached substances, 
drug binding to plasticizer and drug degradation by leached 
material have been reported to be other problems in the tube 
fed patient (114,118,119,126-132).
From the literature reports it is clear that a wide 
range of interactions may occur between tube materials, 
drugs and enteral nutrient formulas. These interactions may 
lead to degradation of essential nutrients present in the 
formula or antagonism or altered bioavailability of drugs 
administered by the feeding tubes. In order to knowledgeably 
use this procedure for the administration of drugs it is 
necessary to evaluate further the delivery of drugs by 
feeding tubes. Other aspects such as interactions between 
food and drugs, drugs and drugs, food and tube material, 
drugs and tube materials must also be evaluated. The above 
studies should be extended to different drugs with different 
food formulas in a variety of enteral feeding tubes. It is 
essential to have delivery as well as pharmacokinetic data
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
available for drugs most commonly administered by enteral 
feeding tubes to critically ill patients for long term use. 
Data concerning quantitative delivery of drugs by feeding 
tubes and pharmacokinetics may permit a clear understanding 
of the effectiveness of treatment and evaluation of the 
patient's recovery. Considering the problems associated with 
the delivery of drugs by enteral feeding tubes it will be 
essential to conduct delivery studies for drugs by different 
feeding tubes. Studies should be conducted with and without 
nutrient formulas.
Since all types of feeding tubes, IV tubes and infusion 
bags are made of similar materials, results from one study 
can be used to correlate to other tubes made of the same 
material, i.e., to the other feeding tubes made of the same 
material.
Sorption of drugs and chemicals to polvmeric materials
Sorption is a physicochemical phenomena that can occur 
when a solution is in contact with a solid phase (86). 
Sorption can occur as a result of two phenomena. If the 
solute interacts with the surface of the solid then it is 
adsorption whereas if the solute penetrates into the solid 
matrix then it is termed absorption. Absorption occurs as a 
result of diffusion of the solute molecule into and within 
the matrix of the solid (90). Since solute absorption is a 
diffusion process it takes a longer time and can involve 
larger amounts of material when compared to adsorption (96). 
Adsorption occurs more rapidly (86). It reaches equilibrium 
faster, and desorption is easier unless the interaction 
between the drug and the solid material is quite strong 
(96), The amount of drug adsorbed is likely to be smaller 
than the amount absorbed.
Since sorption is a physicochemical phenomenon, 
sorption of drugs to tubing material is directly related to 
the chemical structure of the drug and the physical and 
chemical properties of the tubing material (98). Other
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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factors such as concentration, solvent system, other agents 
in the solution, pH of the solution, temperature, time of 
contact, amount of surface exposed to solution, purity of 
material and possible changes in the material after exposure 
to solution may also be involved in this process. 
Interactions may be ion-ion, ion-dipole, dipole-dipole or 
through secondary valance forces such as Van der Waals 
forces or perhaps a combination of these (98), The affinity 
of a drug for a specific plastic material can be indicated 
in terms of standard chemical potential. If the rate 
determining step in the sorption process is diffusion of the 
drug into the matrix of the plastic, then importance is 
placed upon the diffusion constant or coefficient. Solute 
molecules within the solvent diffuse toward the surface of 
the plastic and become adsorbed. When most of the adsorption 
sites are occupied, there will be sufficient energy to 
permit these solute molecules to penetrate the surface and 
to travel or diffuse into the amorphous zone of the plastic 
where new binding sites become available (98). If no more 
sites are available then equilibrium has been reached at 
that particular solute concentration and time.
Plastic or rubber polymers are composed of crystalline 
regions dispersed throughout amorphous regions. The 
permeability of polymers may differ due to molecular weight, 
molecular weight distribution, branching, degree of 
crystallinity and the presence of other ingredients (136). 
Extensive cross linking within the polymer retards the 
movement of solute particles, thus less permeation occurs. 
Since an amorphous zone has low crosslinking, more 
permeability (easier diffusion) is observed in this region 
than in a moderate to high crystalline region. A low 
diffusion constant results for high crystalline region 
(136). Highly crystalline polymers are rigid in nature. To 
make formulated polymers soft and flexible, plasticizer and 
other additives such as stabilizer, filler and lubricant are 
added to the material. In any formulated plastics there is
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
always a propensity for one of the ingredients to migrate 
into the environment which has intimate contact with the 
material (130). Leaching may modify the structure of the 
plastic matrix, thereby altering its permeability. Additives 
leached from any of the polymer materials may interact with 
the drug. The chemistry of a number of polymers utilized in 
plastics suggest that a medicinal agent conceivably could be 
bound to certain polymers (96). Polymers containing charged 
negative centers such as carboxyl groups could react with 
proton donating agents forming an intermolecular complex. A 
number of such intermolecular interactions have been 
reported for macromolecules having acidic hydrogens (137). 
Reactivity due to sorption (absorption and/or adsorption) 
has been found to occur frequently with the polyamide 
polymers (137). Though the exact mechanism is not determined 
it could be that the carbonyl groups of the polyamides acted 
as negative charged centers attracting the proton donating 
groups of phenols, the main forces of bonding being through 
hydrogen bonds. In dilute solutions, drug molecules are not 
hindered in approaching the binding sites on the surface and 
within the polymer, but as the concentration is increased 
there is hindrance to the approach of the molecules for the 
remaining sites (137). However there appears to be a 
critical concentration level where the solution can 
literally break through the polymer matrix. Once this has 
occurred a great many sites are available (137).
Thus, loss of drug could occur by adsorption of a 
nonpolar drug onto the tubing surface, absorption of the 
nonpolar drug into the tubing, or partitioning of the drug 
into the tubing (97).
Purpose and objectives of this studv
Triazolam (Halcion^) and baclofen (Lioresal^) are 
commonly administered to spinal cord injury and post-stroke 
patients through G-tubes. Since these patient conditions 
prevent them from taking food and drugs by mouth they are
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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fed through feeding tubes. Both triazolam and baclofen are 
available only in tablet form, so they must be crushed to 
make a slurry and administered through feeding tubes. No 
data has been reported regarding the quantitative delivery 
of these drugs by G-tubes or any other drug delivery devices 
made of similar materials.
This study was conducted in-vitro using the two most 
common G-tubes in practice, the rubber Foley catheter and a 
replacement G-tube (Ross flexiflo #154). The major purpose 
of this thesis was to study the sorptive interaction between 
triazolam and baclofen with two types of G-tubes in current 
clinical use. This was studied by evaluation of the delivery 
of triazolam and baclofen by G-tubes using conditions which 
simulate but do not duplicate the clinical conditions used 
for administration of these agents. Thus delivery of 10 mg 
of baclofen or 0.25 mg of triazolam in 10 ml of water was 
evaluated. Two types of studies were conducted for each drug 
and each tube under study, static (equilibrium) studies and 
dynamic (flow) studies. Depending on the drug loss in static 
(equilibrium) studies, further studies at different 
concentrations and at various intervals were done.
This project could serve as the initial phase of 
studies to characterize the absorption and disposition of 
drugs in patients requiring medication delivery by G-tubes. 
Results of the delivery of these drugs by G-tubes could be 
used to make recommendations regarding the selection of an 
appropriate G-tube with minimal or no drug loss for patients 
requiring long term use. This study may also be helpful in 
the development of suitable dosage forms which would enhance 
the delivery of these and other drugs through G-tubes.
Chemical Structures
H,NCh,CMCH,COOH
L
Triazolam
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EXPERIMENTAL
MATERIALS 
Gastrostomy tubes;
1) Foley Catheter
Bard Urological Division
C.R. Bard, Inc., Covington, Georgia 30209
2) Flexiflo Gastrostomy Tube, 18 French #154
Ross Laboratories, Columbus, Ohio 43216 
Lot numbers; 45-429-GZ & 46-455-GZ 
Drugs;
1) Baclofen [Lioresal^] 10 mg tablet 
Geigy, Ardsley, NY 10502
Lot numbers: IT108066, IT115898 & IT119303
2) Triazolam [Halcion^] 0.25 mg tablet 
The Upjohn Co., Kalamazoo, MI
Lot number: 440 DY
3) Triazolam (8-chloro-6-(2-chlorophenyl)-l-methyl-4H- 
1,2,4-triazolo [4,3-al]-1,4-benzodiazepine)
(M.W. 343.21)
Sigma Chemical Co., T-9772, Lot-19F4021
4) Baclofen (4-amino-3- [4-chlorophenyl butanoic acid)
C 10H 12CINO2 (M.W. 213.67)
Sigma Chemical Co., B-5399, Lot-38F0508 
Reagents:
1) Methanol, HPLC grade, Fischer Chemical
2) Monobasic Potassium Phosphate, Allied Chemical
3) Sodium Acetate GR, EM Science
4) Acetone
5) Sodium Hydroxide, Reagent Grade, J.T. Baker Chemical Co.
Foley catheters are 43 cm in length, Ross Flexiflo G- 
tubes measured 26 cm and both are 18 French in diameter. The 
internal diameters for Foley catheter and Ross tubes are 0.3 
cm and 0.45 cm respectively. Triazolam is a tan crystalline 
powder and is very slightly soluble in water. Baclofen is 
crystalline and is slightly soluble in water.
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METHODS
Analytical Methods
Triazolam was analyzed by the reversed phase HPLC 
procedure described by Inoue and Suzuki (141), and baclofen 
by the procedure of Wuis et al. (142). A LDC/MILTON ROY 
series 3000 high performance chromatograph equipped with a 
variable wave length UV/visible detector and a 01 4000 
computing integrator was used. The analytical column was an 
Altech econosphere (250 mm x 4.6 mm, 5 micron reversed phase 
CIS column). Triazolam was eluted with a mobile phase of 
methanol:10mm phosphate buffer pH 8, in a ratio of 65:35 at 
a flow rate of 0.8 ml/min, with analysis at a wavelength of 
220 nm at 0.02 aufs or 0.1 aufs, dependent upon 
concentration.
The procedure for baclofen utilized a mobile phase of 
methanol: 0.02 M sodium acetate in a ratio of 85:15 at a 
flow rate of 0.7 ml/min using a wavelength of 220 nm at 0.2 
aufs.
Retention times for triazolam and baclofen were 9.5 ± 
0.1 and 5.6 ± 0.1 minutes, respectively.
Procedure :
The column was prepared by elution with the water 
followed by mobile phase for at least 10 to 15 column 
volumes each. The detector was adjusted for wave length, 
absorption units full scale (AUFS), and response time. The 
pump flow rate was adjusted based on the peak times of 
authentic samples. Sample injections were made using a 20 
mcl injection loop which was filled using 60-100 mcl of 
sample solution. Relative peak areas were determined by the 
integrator, which was set for appropriate baselines and skim 
ratios. Sample quantification was made based on the 
integrated area under peak. All injections were made at 
least in triplicate. Sufficient column washing time was 
allowed between the sample injections. At the end of the 
sample analysis the column was thoroughly washed with mobile
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phase followed by water and finally parked under methanol. 
After a series of injections were completed, the data could 
be recalled from computer memory and reprocessed to evaluate 
the baseline and peak area integration. If the baseline was 
not consistent with initial baseline corrections, then the 
injection data was reprocessed to correct the error in the 
peak area calculation.
Standard curves for triazolam and baclofen
Standard curves for triazolam and baclofen were 
prepared using authentic samples of drugs in known 
concentration in water. Serial dilutions were made from the 
highest concentrations. Additionally, standard curves were 
made from tablet solutions under identical conditions. These 
standard curves covering the concentration ranges used in 
all experiments, were used to set the instrumental 
conditions for sample analysis, to correlate peak area and 
concentration, to evaluate the extent of drug dissolution 
from the powdered tablet, to study the reproducibility of 
experiments and to determine the amount of drug lost to the 
G-tubes from the drug solutions.
Standard curves for triazolam were made in two 
concentration ranges (25-100 and 2-25 mcg/ml) using tablet 
solutions and one concentration range using triazolam 
standard (10-100 mcg/ml). Standard curves using baclofen 
tablet solution and authentic sample were made from a 
concentration range of 200-1000 mcg/ml. Standard curves for 
triazolam and baclofen are shown in Figures 1-5.
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Standard Carve for Triazolam  (Standard)
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Figure 1. Standard curve for Triazolam standard in water 
(10-100 mcg/ml)
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Figure 2. Standard curve for Triazolam tablets in water 
(25-100 mcg/ml).
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Figure 3. Standard curve for Triazolam tablets in water 
(2-25 mcg/ml)
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Standard Currc fa r  Baclofen (Standard)
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Figure 4. Standard curve for Baclofen standard in water 
(200-1000 mcg/ml).
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Figure 5. Standard curve for Baclofen tablets in water 
(200-1000 mcg/ml).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
17
Dissolution studv for triazolam
Since triazolam is very slightly soluble in water 
dissolution studies were conducted to study the extent of 
solubility in water. Two triazolam tablets were dissolved in 
50 ml water at a stirrer speed of 50 rpm. Samples were drawn 
at regular intervals, filtered and analyzed for the 
dissolved drug (Figure 6).
Preparation of test solutions
Tablets were powdered in a porcelain mortar and the 
powder was dissolved in water to obtain the required 
concentration. The solution was stirred on a magnetic 
stirrer at a speed of 250 rpm for 30 min, and was filtered 
under suction through a No.2 Whatman filter paper to remove 
undissolved excipients. The filtered test solutions were 
stored in glass vials with plastic screw caps.
Triazolam
Solution A; Six Halcion^ 0.25 mg tablets were dissolved in 
15 ml distilled water to obtain a concentration of 100 
mcg/ml. This solution was used to make further dilutions of 
required concentration.
Solution B: Two Halcion^ 0.25 mg tablets were dissolved in 
20 ml distilled water to obtain a drug concentration of 25 
mcg/ml. This solution was used to make further dilutions. 
Baclofen
Four Lioresal^ 10 mg tablets were dissolved in 40 ml 
distilled water. Further dilutions were made from this 1000 
mcg/ml solution.
Deliverv (Sorption^ Studies
The tubes or cut tube segments were filled with the 
drug solution using a plastic syringe, clamped at both ends 
and allowed to stand at ambient temperature (20°C) for 24 
hours. After 24 hours the solutions were drained and 
analyzed for drug content. This result was compared to the 
control, which was obtained from the solution stored in
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Dissolution of Triazolam Tablets 
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Figure 6. Dissolution study for Triazolam tablets in water.
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glass vials for an equal time. To evaluate the possibility 
of drug loss to glass, the test solution was analyzed before 
and after storage in the glass vial. Similarly, loss of drug 
to the plastic syringe used to inject the sample into the 
tube also was evaluated by comparing the control stored in 
glass to that of the syringed control. The results from the 
stability analysis of the solution stored in glass vials 
were also applicable to potential drug loss to the glass 
used in mixing and to the glass syringe used to inject 
samples into the column.
The 24-hour sorption studies described above were 
performed in order to evaluate the drug loss to the G-tube 
under "worst-case" conditions. In the clinical environments 
the drug normally is in contact with the G-tube only for a 
matter of minutes, never for hours. Therefore, exposure of 
the drug solution to the G-tube for 24 hours would evaluate 
the maximum drug loss in any clinical setting. Loss of drug 
was observed only with triazolam but not with baclofen. 
Therefore, with triazolam further studies to evaluate the 
drug loss were performed as below.
I) Static (equilibrium) studies:
A) 24-hour sorption studies
B) if loss was observed in part A
1) reversibility of loss (desorption)
2) variability of tubes: inter and intra
3) dependence of loss on:
a) time of contact with internal surface
b) concentration of the sample
c) surface area of the tube exposed
d) prewashing of tubes
II) Dynamic (flow) studies:
III) Clinical simulation studies;
IV) Other Studies:
A) study of leaching
B) study of nature of loss
C) study of extent of loss
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IA) 24-hour Sorption Studies {Baclofen and Triazolam):
The 24-hour studies were performed as described above,
IB) Further Studies (Triazolam):
1) Reversibility of loss (desorption):
Into the same tubes used in experiment lA water was 
stored for 24 hours at ambient temperature. After 24 hours 
the water was drained from the tube and was analyzed for 
recovered drug. Control for this experiment was water not 
stored in the tube and also water stored in a fresh tube for 
the same amount of time.
2) Variability in tubes:
Tubes were tested for variability of drug loss within 
the tubes and between the tubes. Variability was studied 
with the same sample concentration as well as for different 
concentrations.
a) Inter-tube variability with the same solution 
concentration:
Different tubes of the same kind were studied for 
variability between the tubes. The same drug solution was 
used to fill different tubes and the experiment was repeated 
as in lA. All the samples were analyzed under identical 
conditions and compared against the control solution stored 
in glass.
b) Inter-tube variability with different solution 
concentrations :
As in experiment 2a, solutions of different 
concentrations were placed into different tubes and the 
conditions of experiment lA were repeated. Control solution 
for each tube was that of the test solution stored in glass. 
The results were compared to that of the control, and the 
variability in sorption with respect to concentration in 
different tubes was evaluated.
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c) Intra-tube variability:
Each tube was cut into four pieces. The first and third 
sections were filled with a 100 mcg/ml solution of triazolam 
and the second and fourth sections were filled with a 50 
mcg/ml solution. All sections were clamped at both ends and 
the experiment was repeated as in lA. Samples were analyzed 
and compared against control (100 mcg/ml solution for 
section 1 and 3 and with 50 mcg/ml for section 2 and 4). The 
variability in drug loss within the same tube and with 
respect to different concentrations was evaluated.
The above experiment was repeated with 25 mcg/ml and 10 
mcg/ml concentrations in a separate tube. These results were 
combined to evaluate the variability between the tubes, and 
within the tubes for the same as well as different 
concentrations.
3a) Dependence of loss on time:
Two tubes were cut into four pieces each, into each 
part the same test solution was placed, and the tubes were 
clamped at both ends. Samples were drained from the tubes at 
the following intervals.
Tube Section Time
A 1 0.5 hr
2 1 hr
3 2 hr
4 4 hr
B 1 4 hr
2 8 hr
3 12 hr
4 24 hr
Samples were analyzed and the results were compared to 
that of control stored in glass.
3b) Dependence of loss on concentration:
Four different concentrations of the test solution 
(100, 50, 25 and 10 mcg/ml) were placed into four different 
tubes and the experiment was performed as in lA. Samples 
were drained and analyzed for the drug. The results were
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compared to that of the control solution for each tube (100, 
50, 25 and 10 mcg/ml) and loss of drug with respect to the 
concentration was determined.
The above experiment was repeated using a fresh tube 
cut into four pieces. Into each section different 
concentrations were placed. The samples were analyzed and 
compared to the respective control.
3c) Dependence of loss on the surface area of the tube
exposed:
The following experiment was conducted to study the 
relationship between drug sorption and the surface area 
(internal surface) of the tube to which the drug was 
exposed. In this experiment, tubes of the same internal 
surface area were exposed to three different volumes of the 
same drug solution. Into three tubes, was placed 1, 2 and 3 
ml of the drug solution (100 or 25 mcg/ml) and the tubes 
were clamped at both ends. The tubes were attached to a 
rotating blender and revolved at a speed of 30 rpm for 2 
hours, samples were drained and analyzed for drug content. 
Results were compared to that of control to evaluate the 
loss of drug with respect to surface area of the tube.
3d) Effect of prewashing of tubes on delivery of drug:
One tube was cut into four equal parts and each part 
was washed with water for different periods of time at the 
same washing rate.
Section Washing time
a 2 min
b 10 min
c water stored in tube for 24 hr
d unwashed
After the washing procedure, the tubes were used to 
study the effect of washing on leaching of substances from
the tube as well as sorption of drug. Test solutions of the
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same concentration was stored in each section of the tube 
and experiment lA was repeated. Test results were compared 
to the control to identify the effect of washing.
II. Dynamic (flow) Studies (Triazolam);
In order to evaluate the delivery of drugs through G- 
tubes, it was necessary to study the loss of drug in a 
dynamic mode as drug solutions pass through the tube. 
Therefore, to understand the delivery more clearly this 
study was conducted with triazolam at two different flow 
rates, 1 ml/min and 25 ml/min.
Two 0.25 mg tablets of triazolam were crushed and 
dissolved in 50 ml water and this solution was placed in a 
30 ml syringe. The G-tube was attached to the needle 
attachment hub of the syringe and the solution was run 
through the tube at 1 or 25 ml/min by means of a syringe 
pump (Sage instruments, model 355). Samples were collected 
every 5 min for 1 ml/min and every 0.2 minutes (12 sec) for 
25 ml/min. Samples were filtered and analyzed for drug 
content. The results were compared against three controls. 
The first control was the solution before taking into the 
syringe, the second control was the solution from syringe 
but before the experiment and the third control was the 
solution collected towards the end of the experiment from 
the syringe. After all the solution was expelled from the 
syringe, the G-tube and syringe were washed with about 50 ml 
water. The water washings were collected and analyzed for 
the drug content.
III. Clinical Simulation Study (Baclofen and Triazolam):
In hospitals patients fed through gastrostomy tubes are 
given "oral" medications via the G-tube. Medications 
available as tablets are crushed and made into a slurry in 
about 10 ml of water in order to facilitate the delivery 
through tubes. After the drug is given the tube is washed 
with 50 ml water to wash the possible remains of the drug as
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well as to avoid any clogging in the tube.
The following procedure was used to simulate the 
delivery of drugs via G-tubes. Two tablets were crushed and 
made into a slurry in 20 ml water. The slurry was shaken 
manually for several minutes, then 10 ml of the slurry was 
drawn into the syringe and injected through the feeding 
tubes in about 1/4 to 1/2 minute. This solution contains 
about one tablet quantity of drug. The syringe and tube were 
washed with 50 ml water. Drug solution from the tube was 
collected in one volume and the washings were collected in 
10 ml portions each. The remaining 10 ml portion of the 
initial drug solution was used as control. The test results 
were compared against the control to see how much drug was 
delivered through the G-tube, and the water washings were 
analyzed to see if a measurable amount of recoverable drug 
remained in the tube. This simulation study was also 
repeated with filtered solutions.
IV. Other studies;
A) Study of leaching:
From the previous studies it was noted that the 
solutions exposed to the G-tubes contained several peaks in 
the HPLC chromatograms which were not present in the control 
solutions. One peak, which eluted prior to the drug, 
appeared to increase as the solution was stored longer in 
the tubes. This peak decreased as the tube was used 
repeatedly, i.e., it was more prominent in the fresh tubes 
than in the older ones. Several experiments were done in 
order to evaluate this leaching of material from the G- 
tubes.
Leaching into water:
Water was stored in two tubes for 24 hours, drained and 
analyzed for the presence of leached material under the same 
conditions as in the other experiments. The above experiment 
was repeated with drug solution in the same tube and fresh
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tubes, and the appearance of leached material and total 
amount of drug lost was compared between the two tubes.
In the experiment on the effect of leaching on drug 
sorption, one tube was cut into two pieces and one part was 
filled with water and the other part with drug solution. The 
results were compared to determine if the leaching varies 
with the nature of the solution (e.g pH, polarity). This 
experiment was repeated with the same parts of the tube but 
with the drug solution into both sections. Results were 
compared to determine if the loss was the same or if a prior 
water wash has any effect on the leaching or drug sorption.
Effect of solvent pre-treatment on leaching and sorption:
Two tubes were cut into two pieces each. One part of 
each tube was filled with methanol and acetone separately 
for 12 hours. Solvents were drained and tubes were dried for 
about an hour in the room temperature. Experiment lA was 
repeated for each section of each tube with the drug 
solution. Results were compared to study the effect of pre­
treatment of the tube with organic solvents on leaching, and 
subsequent sorption of drug.
B) Study of nature of loss:
One tube was cut into two pieces and drug solution was 
stored in each piece for two hours, then samples were 
drained and analyzed. One part of the tube was not washed 
with water before repetitions whereas the other part of the 
tube was washed with water between experiments. The above 
experiment was repeated 10 times and the results of each 
trial was compared with the control and also to the previous 
trials. This experiments provide information as to whether 
the loss was due to adsorption or absorption and also if the 
washing promotes or inhibits the loss. In each trial, the 
same sample solution was used in the washed and unwashed 
sections. The washed tube was dried in air before filling 
with the solution.
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C) Extent of drug loss:
Pseudo-equilibrium study:
One fresh tube was washed with 10 liters of water and 
then cut into four equal parts. Into each part of the tube 
drug solution was placed, the tubes were clamped at both 
ends and samples were collected in the following order for 
analysis.
Tube section Time of sample collection
a 12 hrs
b 24 hrs
c 48 hrs
d 72 hrs
Results of each sample was compared with the control 
and with each other to evaluate the equilibration of drug 
loss to the tubing.
DATA INTERPRETATION
Test samples and controls were analyzed under the same 
conditions using the same analytical procedure. All 
experiments were repeated at least 3 times and the results 
were compared for reproduceabi1ity. In all experiments, test 
results were compared to that of the appropriate controls. 
Data corresponding to all variables were evaluated for one­
way analysis of variance.
Drug loss is reported as percent of loss in comparison 
to controls. Quantification of drug present in samples was 
made by integrated peak areas of the HPLC chromatogram. No 
internal standard was used. The difference between the 
amount of drug remaining in solution exposed to the tube and 
that in the control solution stored in glass for the same 
amount of time (as indicated by differences in the areas 
under peaks) was assumed to be the drug sorbed by the tube.
Results of the surface area experiments were reported 
as loss per square centimeter of the tube. The total surface 
area which the drug solution was exposed to was determined
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from the interior dimensions of the tubes under study- In 
the reversibility of drug loss (desorption) studies, water 
was used as control and recovery was estimated as percent of 
recovery of the sorbed drug. Intra- and inter-tube 
variability was studied by comparing the percent drug loss 
within different parts of the same tube and different tubes 
of the same kind. Samples in the flow studies were 
collected in fractions and the loss was reported for the 
particular fraction. In the clinical simulation study, drug 
loss was estimated only for bolus administration.
Since controls of authentic samples did not show any 
additional peaks other than the sample peak, peaks that 
appeared with the test solutions stored in tubes were 
attributed to the leached substances from the tubes. 
Identical peaks were observed following storage of water in 
the tubes, substantiating that the peaks were due to the 
presence of leached substances and not due to drug break 
down. Since peaks of leached substances had different peak 
(elution) times and appeared not having any effect on the 
sample peak, they are not considered in the data analysis.
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RESULTS
STATIC (EQUILIBRIUM) STUDIES IN FOLEY CATHETERS:
SORPTION STUDIES FOR TRIAZOLAM:
The results of sorption studies in which solutions of 
triazolam were stored in Foley catheters are shown in Table 
I. Concentrations in all studies are in mcg/ml.
Table I: Sorption studies for Triazolam in Foley catheters
Exper Tube Cone % loss % R Loss . 
Mcg/cm*^
Final
cone
1 I 100 36 100 2.70 64
2 I 100 42 101 3.15 58
3* I 0 0 0 0.00 0
4 I 100 62 100 4.65 38
5 I 100 39 104 2.92 61
II 100 25 104 1.87 75
6 I 50 25 103 0.94 38
II 100 35 100 2.62 65
tube.
%R Percent remaining control.
From the results in Table I it can be seen that between 
25-62% of triazolam was lost to the tubing when solutions of 
the drug were stored in the tubes for 24 hours. No loss was 
observed for the control solutions stored in glass during 
the same period. Tube I showed a variability in loss 
depending on the pre-treatment of the tube and on the 
concentration of the solution studied. After the desorption 
study in experiment 3, this tube showed greater loss in 
experiment 4 than in the other trials. A smaller drug loss 
was observed in tube I when the concentration of the test 
solution was decreased from 100 mcg/ml to 50 mcg/ml in 
experiment 6. Even after four trials, tube I showed more 
drug uptake than tube II in its first or second trials as 
seen in experiments 5 and 6.
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DEPENDENCE OF DRUG LOSS ON CONCENTRATION:
Drug uptake by G-tubes was studied in different Foley 
catheters and in the different sections of the same Foley 
catheter with different concentrations. The results of these 
studies are shown in Tables II, III and in Figure 7-
Table II: Sorption studies for Triazolam: Different drug
concentrations in different Foley catheters.
Tube # Cone % loss % R Loss . 
Mcg/cm^
Final
cone
I 100 41 102 3.07 59
II 50 30 100 1,12 35
III 25 21 97 0.39 20
IV 10 11
--;--I------- :---=
100 0.08 9
Table III: Sorption studies for Triazolam: Different drug
concentrations in different sections of the same 
Foley catheter.
Sect Cone %
tube I
loss
tube II
% R Loss _ 
Keg/car 
I II
Final 
cone 
I II
a 100 62 63 100 4.43 4.50 38 37
b 50 55 65 100 1.96 2.32 23 18
c 25 59 34 100 1.05 0.60 10 17
d 10 22
k-j-
39 101 0.16 0.28 8 6
The results in Table II show a concentration dependent 
loss in four different Foley catheters. The percent of drug 
lost to tubing decreased as the concentration decreased from 
100 mcg/ml to 10 mcg/ml. The percent of drug loss was 41% 
with the 100 mcg/ml solution followed by 30%, 21% and 11% 
with 50, 25 and 10 mcg/ml solutions respectively.
Results from experiments on loss of triazolam at 
different concentrations in different sections of the same 
Foley catheters showed a variable drug loss. The results in 
Table III showed higher drug loss in sections a and b, in
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Figure 7. Dependence of Triazolam loss on concentration in 
Foley catheters.
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which 100 and 50 mcg/ml solutions were placed. Sections c of 
tube I, b and d of tube II showed higher drug loss than the 
preceding higher concentrations. The overall trend in drug 
loss seemed to be concentration dependent in both tubes; 
i.e., a greater percent was lost at higher concentrations. 
DEPENDENCE OF THE LOSS ON TIME:
Experiments on loss of drug with respect to time were 
conducted in two Foley catheters cut into four sections 
each. The dependence of drug loss on time is also shown in 
Figure 8 for 25 mcg/ml solution and Figure 9 for 100 mcg/ml 
drug solution. Table IV shows the results of loss of drug 
with respect to time with 25 mcg/ml solution and table V 
with 100 mcg/ml solution.
Table IV: Sorption studies for Triazolam: Dependence of loss 
on time with 25 mcg/ml solution.
Time(hr) Tube % loss % R Loss _ 
Mcg/cm^
Final
cone
0.5 la 23 100 0.41 19
1 Ib 23 100 0.41 19
2 Ic 24 101 0.43 19
4 Id 24 101 0.43 19
4 Ila 26 101 0.46 19
8 Ilb 27 105 0.48 18
12 lie 33 97 0.59 17
24 Ild 52 97 0.93 12
Table V: Sorption studies for Triazolam; Dependence of loss 
on time with 100 mcg/ml solution.
Time(hr) Tube % loss % R Loss _ 
Mcg/cm^
Final
cone
0.5 Ilia 39 100 0.70 15
1 m b 35 100 0.62 16
2 m e 46 101 0.82 14
4 H i d 48 101 0.86 13
4 IVa 30 101 0.54 18
8 IVb 36 98 0.64 16
14 IVc 47 98 0.84 13
24 IVd
i k
51 97 0.91 12
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Figure 8. Dependence of Triazolam loss in Foley catheters 
with 25 mcg/ml solution.
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Figure 9. Dependence of Triazolam loss in Foley catheters 
with 100 mcg/ml solution.
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From Tables IV and V and Figures 8 and 9, it can be seen 
that drug loss to tubing is time dependent with both 25 
mcg/ml and 100 mcg/ml drug solutions. Significant drug loss 
was observed within one half hour. The rate of drug loss 
appeared to decrease after the initial rapid loss. This was 
evident from table IV, in which 23% of the initial drug was 
lost in the first half hour, but it increased to only 27% at 
eight hours, to 33% at 12 hours and to 52% at 24 hours. 
Similar drug loss was observed with 100 mcg/ml drug solution 
as shown in Table V except for the inter-tube variability 
between tubes III and IV. There was no significant inter­
tube variability between tubes I and II as shown in Table
IV.
STUDY OF EXTENT OF DRUG LOSS:
Drug loss observed for extended periods of time (12,
24, 48 and 72 hours) in different sections of the Foley 
catheters is shown in Table VI and in Figure 10. In these 
experiments two different Foley catheters were cut into four 
sections each.
Table VI: Sorption studies for Triazolam: Drug loss 
extended periods in Foley catheters.§
for
Tube Time %loss % R Loss Final
(hr) tube I tube II Mcg/cm^ cone
I II I II
a 12 26 27 100 0.46 0.48 19 18
b 24 27 26 101 0.48 0.46 18 19
c 48 56 51 100 1.00 0.91 11 12
d 72 62 52 99 1.10 0.93 10 12
% R: Percent remaining control.
§: Concentration 25 mcg/ml.
As observed in the previous experiments there was an 
initial rapid drug loss followed by a slower, time-dependent 
drug loss. About 26-27% of the initial drug was lost in 12 
hours. No significant drug loss was observed during the next 
12 hours. Another 25-26% of the drug was lost from 24 to 48 
hours, but little loss was observed in the next 24 hours.
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Figure 10. Extent of Triazolam loss in Foley catheters with 
25 mcg/ml solution.
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DEPENDENCE OF LOSS ON VOLUME OF DRUG SOLUTION AT CONSTANT 
SURFACE AREA OF THE TUBE:
Experiments to determine the dependence of drug loss on 
the exposed surface area of Foley catheters were conducted 
in three different Foley catheters. Each catheter was 
studied with a different volume (1, 2 or 3 ml of drug 
solution). Results of these experiments are shown in Table 
VII.
Table VII: Sorption studies for Triazolam: drug loss with 
respect to tÿe volume of solution at constant 
surface area of the tube.§
Tube # Volume % loss Initial
amount
Meg
loss
Meg
rem.
Loss . 
Mcg/cm^
Final
cone
A 3 ml 10 75 7.5 67.5 0.19 22.5
B 2 ml 11 50 5.5 44.5 0.14 22.2
C 1 ml 12 25 3.0 22.0 0.08 22.0
D 3 ml 12 75 9.0 66.0 0.23 22.0
E 2 ml 12 50 6.0 44.0 0.15 22.0
F 1 ml 15 25 3.8 21.3 0.10 21.3
@ : concentration 25 mcg/ml,
*; Surface area of the tube to which the drug solution was 
exposed was calculated from the internal dimensions of 
the tube.
These results show that while the percent of the drug 
loss was about the same for the 3 different quantities of 
drug solution used, the amount of the drug lost (in meg) is 
dependent upon the total amount of drug exposed to the tube. 
Thus approximately 7.5 meg of drug was lost in tube A, 5.5 
meg in tube B and 3 meg in tube C. Similarly, 9, 6 and 3.8 
meg of drug was lost in tubes D, E and F respectively. The 
amount of drug loss per cm^ of the tube exposed is related 
to the total amount of drug exposed, i.e., more drug is lost 
with higher volumes and greater amounts. Final concentration 
of the drug solution is same for all volumes.
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TUBE VARIABILITY:
Inter-tube variability (Variability between Foley 
catheters):
Tube variability between different Foley catheters was 
studied both with different drug concentrations and with 
equal drug concentration. These results are shown in Tables 
VIII and IX.
Table VIII: Sorption studies for Triazolam: Variability 
between different Foley catheters with a 
constant concentration.
Tube # Cone %loss % R Loss . 
Mcg/cm^
Final
cone
V 100 37 102 2.77 63
VI 100 25 104 1.87 75
VII 100 70 97 5.25 30
VIII 100 75 97 5.62 25
IX 100 41 102 3.07 59
X 100 46 102 3.45 54
% R: Percent remaining control.
Table IX: Sorption studies for Triazolam: variability
between different Foley catheters with different
drug concentrations.
Tube # Cone %loss % R Loss . Final
Mcg/cm*^ cone
I 100 41 102 3.08 59
II 50 30 100 1.12 35
III 25 21 97 0.39 20
IV 10 11
-i ..... .
100 0.08 9
Table VIII showed a variable drug loss of 25-75 % with 
equal concentration (100 mcg/ml) in six different Foley 
catheters. As seen in Table IX, four different Foley 
catheters showed a concentration dependent drug loss of 41, 
30, 21, and 11% with 100, 50, 25 and 10 mcg/ml drug 
solutions respectively.
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Intra-tube variability (Variability within the Foley 
catheter):
Different sections (a-d) of the same Foley catheter 
were studied for variability of sorption within the tube. 
Results of intra-tube variability in two Foley catheters 
with four different drug concentrations 100, 50, 25 and 10 
mcg/ml were shown in Table X.
Table X; Sorption studies for Triazolam: variability within 
the Foley catheter with different drug 
concentrations.
Section Cone %
tube I
loss
tube II
% R Loss . 
Mcg/cm^
I II
Final 
cone 
I II
a 100 62 63 100 4.4 4.5 38 37
b 50 55 65 102 2.0 2.3 23 18
c 25 59 34 97 1.1 0.6 10 17
d 10 22 39 101 0.2 0.3 8 6
% R: Percent remaining control.
Both tubes I and II showed a concentration dependent 
drug loss. Variability in drug loss was observed among 
different sections of tube I and II. In tube I, section c 
showed a higher percentage of loss with 25 mcg/ml drug 
solution than with 50 mcg/ml solution in section b. 
Similarly, sections b and d in tube II showed slightly 
higher drug loss than the preceding higher concentrations.
Tube variability within the Foley catheters was studied 
in four Foley catheters cut into two sections each. Each 
tube was studied with 100, 50, 25 and 10 mcg/ml drug 
solution separately. The results of variability within the 
tube with equal concentrations are shown in Table XI.
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Table XI: Sorption studies for Triazolam: Variability within 
the Foley catheter with the same drug 
concentration.
Exper Tube Cone % loss % R Loss - 
Kcg/cwr
Final
cone
1 la 100 77 103 5.5 23
Ib 100 79 103 5.6 21
2 Ila 50 34 99 1.2 33
lib 50 39 99 1.4 31
3 Ilia 25 29 101 0.5 18m b 25 47 101 0.8 13
4 IVa 10 20 99 0.1 8
IVb 10 
• i
24 99 0.2 8
From Table XI it was again observed that drug loss to 
tubing was concentration dependent. In three of the 
experiments there was no significant variability in drug 
loss within the tube with equal concentration. Only tube III 
with 25 mcg/ml drug solution showed variability in sorption 
within the tube. As observed in the earlier experiments, 
drug loss was higher (77-79%) with the highest concentration 
of 100 mcg/ml and dropped to the lowest (20-24%) with the 
lower concentration of 10 mcg/ml.
REVERSIBILITY OF DRUG LOSS (DESORPTION):
Sorption studies for triazolam in Foley catheters 
showed significant drug loss to tubing in 24 hours.
Following the sorption studies, the tubes used in the 
sorption studies were tested for desorption of the sorbed 
drug. Results of the sorption and desorption studies are 
given in Table XII.
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Table XII: Sorption studies for Triazolam: Reversibility of 
drug loss in Foley Catheters.§
Exper Tube % loss % Recovery % R Control
1 I 37 NE 102
2 I 42 NE 101
3* I NE 12 0
4 II 50 NE 100
5* II NE 0 0
*: Desorption study.
NE: Not Evaluated.
% R: Percent remaining.
@ : Concentration 100 mcg/ml.
There was 37% and 42% of the drug lost to the tubing in 
experiments 1 and 2. However, in the desorption study from 
this tube in experiment 3 only 12% of the lost drug was 
recovered. In experiment 4 with tube II there was a 50% drug 
loss. No recovery was observed in the subsequent desorption 
study.
EFFECT OF PRE-WASHING OF TUBES ON DRUG LOSS:
Two Foley catheters were cut into four equal parts each 
and each part was subjected to different washing treatments 
before the experiment. Treatments and results are shown in 
Table XIII.
Table XIII: Sorption studies for Triazolam: Effect of
prewashing on drug loss in Foley catheters.
Section Treatment % loss % R Loss I  Final
tube I tube II Mcg/cm^ cone
I II I II
a unwashed 71 75 97 5.1 5.4 29 25
b water, 2 min 46 63 97 3.3 4.5 54 37
c water,10 min 58 56 97 4.1 4.0 42 44
d water,24 hrs 64 58 97 4.6 4.1 36 42
@: Concentration 100 mcg/ml.
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The results of the effect of pre-washing of tubes 
showed more drug loss with untreated sections of the tubes 
(71% and 75%) than after washing. Tubes I and II showed 
variability in drug loss in section b with 2 minute 
treatment. Drug loss in the unwashed sections was followed 
by 10 minute and 24 hour treatment.
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STUDY OF THE NATURE OF DRUG LOSS;
The percent of drug loss in two sections of the same 
Foley catheter is shown in Table XIV. Experiments refer to 
repetitions with section I-UW, which was not washed with 
water between trials, and section I-W which was washed with 
water and dried in air between the experiments.
Table XIV: Sorption studies for Triazolam: Loss of drug in 
washed and unwashed tubes.§
Expt # % loss I-UW % loss I-W % R Control
1 13.0 12.0 101
2 7.4 4.5 101
3 2.8 8.3 100
4 5.0 4.1 100
5 2.0 5.7 100
6 8.8 9.2 101
7 2.8 10.3 101
8 3.9 8.0 101
9 7.6 8.7 101
10 11.8 9.7 101
I-UW: Unwashed tube.
% R: Percent remaining control, 
ê: Concentration 25 mcg/ml.
I-W: Washed tube.
A loss of 2-13% was observed in unwashed and washed 
sections of the Foley catheter in ten trials. The results 
between unwashed and washed sections of the tube and between 
the trials showed a large variability. There was an average 
loss of 6.5% and 8.0% in unwashed and washed tubes 
respectively, in 10 trials. Drug loss was significant even 
after 10 repetitions.
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DYNAMIC (FLOW) STUDIES FOR TRIAZOLAM:
Loss of triazolam from solutions delivered at a flow 
rate of 25 ml/min and 1 ml/min was studied in Foley 
catheters. Results are shown in Tables XV and XVI.
Table XV: Delivery of Triazolam in Foley catheter at a flow 
rate of 25 ml/min.@
Fraction % loss Loss _ Final
tube I tube II Mcg/cm^ cone
I II I II
1 0.6 3.3 0.01 0.04 9.9 9.7
2 2.8 4.0 0.04 0.05 9.7 9.6
3 3.2 2.8 0.04 0.04 9.7 9.7
4 3.8 2.9 0.05 0.04 9.6 9.7
5 2.2 1.1 0.03 0.01 9.8 9.9
§: Concentration 10 mcg/ml.
Table XVI: Delivery of Triazolam in Foley catheter at a flow
rate of .1 ml/min.@
Fraction % loss Loss Final
tube I tube II Mcg/cm^ cone
I II I II
1 5.8 9.7 0.04 0.07 9.4 9.0
2 0.0 2.5 0.00 0.02 10 9.8
3 2.7 +0.25 0. 02 0.00 9.7 10
4 4.0 +2.1 0.03 0.00 9.6 10
5 1.8 0.9 0.01 0.01 9.9 9.9
§: Concentration 10 mcg/ml.
It was evident from these data that little drug loss 
occurred when solutions of the drug were passed through the 
tubes under these conditions. A loss of about 1-4% was 
observed in Foley catheters at a flow rate of 25 ml/min in 
both tubes. At the flow rate of 1 ml/min, 5-10% of the drug 
was sorbed to both tubes in the first fraction. No 
significant drug loss was observed in the later fractions in 
both experiments. The data from fraction 5 suggests that the 
drug loss may decrease as more of the solution passes 
through the tube. This was evident at both 25 ml/min and 1 
ml/min flow rates.
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ROSS FLEXIFLO G-TUBE:
SORPTION STUDIES FOR TRIAZOLAM IN ROSS FLEXIFLO G-TUBE:
Solutions of triazolam were stored in Ross Flexiflo G- 
tubes for 24 hours in experiments 1-9 (In experiment 2 a 
desorption study was conducted) and for 64 hours in 
experiment 10. The same untreated Ross Flexiflo tube was 
used in experiments 1 through 10. Results are shown in Table 
XVII.
Table XVII: Sorption 
G-Tube.
1 studies for Triazolam in Ross Flexiflo
Exper Cone % loss % R Loss _ 
Mcg/cm^
Final
cone
1 25 72 100 2.0 7.0
2@ water 0 0 0 0
3 25 65 100 1.8 8.8
4 12.5 43 102 0.6 7.1
5 12.5 35 101 0.5 8.1
6 25 51 101 1.4 12.3
7 12.5 30 98 0.4 8.8
8 12.5 30 98 0.4 8.8
9 25 47 101 1.3 13.3
10* 25 62 101 1.7 9.5
*: Drug solution was stored in tube for 64 hours. 
% R: Percent remaining control.
Results from Table XVII showed a variable drug loss to 
the tubing. A drug loss of between 30-72% was observed . The 
percent of drug uptake appeared to decrease as the 
concentration of the test solution was decreased and also as 
the number of trials increased. The desorption study in 
experiment 2 might have caused the increase in drug loss 
observed in experiment 3. Drug loss appeared to be time 
dependent, as a greater loss was observed in the 64 hour 
study in experiment 10 than with 24 hour study in the 
previous experiment.
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REVERSIBILITY OF DRUG LOSS (DESORPTION):
Experiment 1 from Table XVII showed 72% of the drug 
loss to Ross Flexiflo G-tube. This same tube was used to 
study desorption of the sorbed drug. Results of this 
experiment are shown in Table XVIII.
Table XVIII: Reversibility of the sorbed Triazolam in Ross 
Flexiflo G-Tube.
Exper Tube # % loss % recovery
1 I 72 NE
2* I NE 11
NE; Not Evaluated.
Results from Table XVIII showed a 11% drug recovery 
from the Ross Flexiflo G-tube, in which 72% of the drug was 
sorbed from 25 mcg/ml solution in the previous experiment.
DYNAMIC (FLOW) STUDIES:
The effect of flow rate on the delivery of triazolam 
was studied in a Ross Flexiflo G-tube with 10 mcg/ml 
solution at a flow rate of 1 ml/min. Results are shown in 
Table XIX.
Table XIX: Delivery of Triazolam in Ross Flexiflo G-Tube at 
a flow rate of 1 ml/min.
Fraction % loss Loss I  Final
Mcg/cm^ cone
Ï tTo Ô7ÏÔ 973
2 4.4 0.06 9.6
3 9.9 0.14 9.0
4 12.9 0.18 8.7
5 9.3 0.13 9.1
From Table XIX it was seen that there was a drug loss 
of 4-13% in the Ross flexiflo tube at a flow rate of 1
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ml/min. Drug loss was significant even in the fifth 
fraction. Loss appeared to be greater in the final three 
fractions than in the initial two. The data from Tables XVI 
and XIX show that the loss of triazolam is greater in Ross 
Flexiflo tubes than in Foley catheters at a flow rate of 1 
ml/min. Drug loss in Ross Flexiflo tube appeared to continue 
longer than in the Foley catheters.
CLINICAL SIMULATION STUDY:
The results of clinical simulation studies for 
triazolam in Foley catheters and in Ross Flexiflo tubes are 
shown in Table XX. In these studies, a slurry/solution 
prepared from triazolam tablets was passed through the 
tubing.
Table XX: Loss of Triazolam in clinical simulation studies 
in Foley catheters and in Ross tubes.
Exp # Tube type Tube # % loss Loss _ 
Mcg/cm'^
Final
cone
1 Foley I +0.5 0.0 25
2 Ross II 7.82 0.5 23
3 Ross
------ 1------  ■"
II +1.0 0.0 25
The first trial in Ross tube (exp #2) showed a drug 
loss of 8% to the tube. No drug loss was observed in the 
second trial (exp #3) with the same tube. There was no 
significant drug loss when the studies were conducted 
following the procedure which is used to administer drugs 
via G-tubes in the clinic with both Foley catheters and Ross 
Flexiflo G-tubes.
EQUILIBRIUM STUDY:
Tables I, IV, V, VI and XIV contain data pertinent to 
the equilibrium study for triazolam in Foley catheters. The 
results of equilibrium studies for triazolam in Ross G-tubes 
are shown in to Table XVII. In Foley catheters, extensive
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drug loss was observed in 24 hours even after the fifth 
exposure of the tube to the drug solution (Table I). The 
drug loss appeared to be time dependent as observed in 
Tables IV, V and VI. The rate of sorption appeared to 
decrease after the initial rapid loss, but then continued 
for extended periods. Drug loss appeared to be significant 
even after 10 trials with the same Foley catheter (Table 
XIV) .
Ross Flexiflo G-tubes showed very extensive drug uptake 
in 24 hours. Table XVII shows concentration and time 
dependent drug loss in Ross G-tubes. The percent of drug 
loss appears to decrease as the trials were repeated in the 
same tube. Drug loss was significant even after nine trials.
BACLOFEN
STATIC (EQUILIBRIUM) STUDIES FOR BACLOFEN;
The results of sorption studies for baclofen in Foley 
catheters and in Ross Flexiflo G-tubes are shown in Table 
XXI.
Table XXI: Sorption studies for Baclofen in Foley catheters 
and Ross Flexiflo G-Tubes.
EXP # TUBE TYPE TUBE # SAMPLE CONC % LOSS
1 Foley I tablet 1000 0.3
2 Foley Ila tablet 1000 0
3 Foley Ilb standard 1000 2.5
4 Ross
é
I tablet 1000 +3.5
Very little or no loss of drug to Foley catheters or 
Ross Flexiflo G-tubes was observed in 24 hours. These 
results indicate that there was minimal or no loss (< 5%) in 
both Foley catheter and Ross Flexiflo G-tubes. Therefore, 
further studies were not necessary.
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CLINICAL SIMULATION STUDY FOR BACLOFEN:
Baclofen slurry/solution samples were injected into the 
tubes in a simulation of clinical conditions. The results 
are shown in Table XXII for Foley catheter and for Ross G- 
tubes.
Table XXII: Drug loss in clinical simulation studies in
Foley catheters and in Ross Flexiflo G-Tubes.
EXP # TUBE TYPE TUBE # SAMPLE CONC % GAIN
1 Foley III tablet 1000 0.68
2 Foley IV standard 1000 0.93
3 Ross II tablet 1000 1.85
As shown in Table XXII, no drug loss was observed to 
Foley catheters or to Ross G-tubes. The observed gain 
(increase) in baclofen was an artifact within experimental 
error.
STUDY OF LEACHING
When the drug solutions were stored in Foley catheters, 
some additional peaks in the HPLC chromatograms of the drugs 
were observed other than that of the drug. Peaks that 
appeared between 3.5 and 4.5 minutes with the drug solutions 
prepared from tablets stored in Foley catheters were partly 
due to excipients in triazolam tablets. These additional 
peaks which were not present in the drug control solutions 
stored in glass would suggest leaching of tube materials 
into the drug solution. Peak areas corresponding to the 
leached substances increased with the increase in time of 
contact and slowly disappeared after few treatments. This is 
illustrated in the chromatograms in figures 11 and 12 for 
triazolam and baclofen solutions respectively.
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Figure 11. HPLC chromatograms showing leaching of tube
materials from Foley catheters into Triazolam 
solutions.
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Figure 12. HPLC chromatograms showing leaching of tube 
materials from Foley catheters into Baclofen 
solutions.
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DISCUSSION
Physicochemical properties play a major role in drug 
absorption from the gastrointestinal tract and also in the 
delivery of drugs by G-tubes. A drug which has low water 
solubility and a lipid-water partition coefficient that 
favors lipid to water has the potential to adsorb onto and 
diffuse into the non-polar materials of delivery tubings. 
Weak organic acids and bases for which the non-ionized form 
has low water solubility will have an increased potential 
for sorption when the solution pH favors the non-ionized 
form. Poor hydrogen bonding capacity also suggests the poor 
water solubility of a compound.
Triazolam is a weakly basic drug with low polarity, low 
water solubility and moderate lipid solubility- Triazolam is 
poorly soluble in water and soluble in alcohol. Baclofen is 
a zwitterionic drug which is slightly soluble in water, 
freely soluble in alcohol and poorly soluble in organic 
solvents, and thus has low lipid solubility. Triazolam is 
mostly non-ionized in aqueous solution whereas baclofen is 
mostly in the ionized form. Since non-ionized drugs have 
increased affinity toward lipids and ionized drugs favor 
water, triazolam is more likely to be sorbed to the delivery 
tubings than baclofen.
At a pH of 7.0, triazolam (pKa 1.52) has a non-ionized 
to ionized ratio of about 300,000:1 (> 99.99% non-ionized). 
The poor water solubility and high ratio of non-ionized to 
ionized molecules in aqueous solution suggests that 
triazolam would have a higher affinity for its own molecules 
and for lipids than for water molecules. This explains its 
poor water solubility and affinity towards the polymeric 
materials. Baclofen, which is highly ionized in water has a 
higher water solubility and lower affinity for lipids than 
triazolam.
Two types of gastrostomy tubes were used in these 
studies. They were teflon coated Foley catheters and Ross 
flexiflo replacement G-tubes made of polyurethane. The Foley
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catheters are constructed with an outer layer of silicone 
rubber and inside this catheter teflon is glued as an inner 
protective layer. Teflon is polytetrafluoroethylene and 
belongs to the halocarbon class of polymer. Polyurethane is 
a member of the natural and synthetic rubber-type polymers 
class.
F F  O H
— C — C— —O—C—N— (CH2 )5“N—C-0—F F  H O
n
Tetrafluoroethylene polyurethane
Chemically both types of polymers are non-polar, inert, 
non-wetable and lipoidal in nature. These polymers are very 
flexible and contain additives. The chemical nature, high 
flexibility and lipoidal nature of the tubes creates a high 
potential for sorption of non-ionized, poorly water soluble 
or lipophilic drugs with similar chemical nature. Between 
these two types of polymers polyurethane has more water 
permeability than teflon.
Baclofen showed very little or no sorption in both 
types of tubes. Triazolam on the other hand was lost in 
significant amounts to both tubes. Loss of triazolam to 
tubes was dependent upon the concentration of the drug 
solution, the time of exposure, the surface area to solution 
volume ratio, the amount of drug exposed and the flow rate. 
Drug loss was irreversible in that it could not be recovered 
from the tubes. Equilibrium was not reached in these studies 
even after extended exposure times. The loss of triazolam to 
the tubes is consistent with an initial adsorption of the 
drug onto the tube surface followed by absorption or 
diffusion of the drug into the tube matrix.
The results of static (equilibrium) studies in Tables I 
and XVII showed a variable loss (25-60%) of triazolam to 
Foley catheters and (30-70%) to Ross flexiflo tubes. This
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loss indicates that triazolam has a high affinity toward the 
hydrophobic polymer substances and that the drug is 
attracted towards the solid tube material from the less 
favored aqueous solutions. This was substantiated by a 
calculation of the standard affinity of triazolam for Foley 
catheters according to the method shown below (136).
Calculation of the standard affinity (a/h) of triazolam for 
the Foley tube from aqueous solutions:
- AM = RT In C2/C1
where, 02 = concentration in the tube,
01 = concentration in the solution.
The ratio of 02 to 01 is the slope of the plot 
of 01 verses 02 (Figure 13).
0.6372, R = 8.314, T = 298.15.
* 298 * In 0.6372 = - 1117
02/01 
~ A/i = 8.314 
A/i = 1117
Concentration in Plastic (C2) vs 
Concentration In Solution (CD
7 0
6 0
5 0o
?  4 0
-  3 0
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Figure 13. Plot of concentration of triazolam in the plastic 
versus concentration in solution.
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Standard affinity is the quantitative measure of the 
tendency of a drug to move from its standard state in liquid 
to the plastic. Standard affinity can also be described as 
the chemical potential of the solute. Calculated standard 
affinity of 1117 indicate that chemical potential of the 
solute is greater in aqueous phase than in the plastic. 
Therefore there was a driving force moving the solute from 
the higher (aqueous) to the lower (plastic) phase. A measure 
of the relative affinity of a solute for the plastic can be 
approximated as the plastic-water partition coefficient. 
Since triazolam is poorly water soluble, liberation of drug 
molecules from water molecules was easier and would have 
required very little activation energy in the transfer 
(sorption) of drug molecules from aqueous solutions to 
tubings. Loss of triazolam to the tubing material could be 
either by adsorption onto the tubing surface or by 
absorption or partitioning of the non-polar drug into the 
tubing. The persistent drug loss observed in repeated trials 
(Table XIV) in the same tube with no tube washing between 
trials indicates that the drug loss is not consistent with a 
monolayer adsorption process. Therefore it could be a multi­
layer formation or, most likely, diffusion into the tube 
materials. Since in most instances adsorption is rapid and 
instantaneous where as absorption is slow and continuous, 
slow equilibration indicates that the drug is absorbed, or 
partitioned, into the tubing.
The amount of drug adsorbed is likely to be smaller and 
more independent of concentration than the amount absorbed. 
The concentration dependent drug loss shown in Tables I, II 
and III for Foley catheters and Table XVII for the Ross tube 
supports the hypothesis of absorption into the tube 
material. Functional groups of plastic which attract or sorb 
the drug molecules act as binding sites in the drug plastic 
interaction. Dilute solutions do not show any significant 
hinderance to the drug molecules in approaching the binding 
sites on the surface of the polymer, but as the
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concentration is increased there is hindrance to the 
approach of the molecules for the remaining sites. The 
relatively large amount of drug loss with respect to 
concentration in Foley catheters shown in Tables II and III 
indicates that there is no hindrance in approach to the 
binding sites at the concentrations used in this study. If 
there was hindrance then concentration dependent drug loss 
would not be possible, because at higher concentrations drug 
molecules compete for the same binding sites resulting 
decrease in sorption at higher concentrations. The 
relationship between concentration of the drug solution and 
the percent of drug loss indicates that uptake is probably a 
function of the total amount of drug available for sorption.
It has been shown that at a critical concentration level, a
solute can literally break through the polymer matrix of the 
tube creating a great many binding sites available for the 
solute molecules to sorb (137). The critical concentration 
level was not evaluated in these studies.
Drug loss in time studies (Tables IV, V and VI for 
Foley catheters and Table XVII for Ross tube) were done over 
time periods up to 72 hours. Equilibrium conditions were not 
reached even after this period, but the rate of loss 
appeared to decrease with increasing time. Time dependent
drug loss was observed in both Foley catheters and Ross
tubes. The time course of drug sorption was most compatible 
with absorption rather than adsorption. Since diffusion is 
the rate determining step in most absorption processes, 
extensive time dependent drug loss supports the phenomena of 
diffusion controlled absorption. When drug absorption is a 
diffusion process it takes a longer time and involves larger 
amounts of material when compared to adsorption. Therefore, 
the observed time course of drug sorption is consistent with 
absorption rather than adsorption. Initial rapid drug loss 
might be attributed to interaction of the drug with the 
surface of the tubing and partly due to absorption of water 
by the polymer at the earlier exposure. Since diffusion is
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the rate determining step in sorption, the initial rapid 
loss followed by slower drug uptake is attributed to drug 
adsorption followed by diffusion of the drug into the 
plastic matrix.
It is possible to envision a model where, when the 
aqueous solutions of triazolam are stored in the tubes, 
triazolam molecules diffuse from solution towards the 
surface of the tube and become sorbed. As the surface area 
is filled there is sufficient energy to permit these solute 
molecules to penetrate the surface and diffuse into the 
amorphous zones of the plastic where new binding sites 
become available. When all sites are filled, equilibrium is 
reached, and no further sorption would occur.
The physicochemical properties of a polymer can be 
altered as a result of contact between drug and tube 
material. Changes in physicochemical properties of the tube 
can possibly change the sorptive nature and capacity of the 
tube material. In some cases when the solution is stored for 
extended periods of time, the solvent can swell and 
plasticize the tube material permitting entry of more drug 
molecules by opening up more passage ways. Since both teflon 
and polyurethane used in this study are poorly wetable 
hydrophobic material with low water permeability, they 
permit water only through porous amorphous zones which 
thereby acts as a plasticizer. It is possible that 
plasticizer from the tube might leach into the solution upon 
prolonged exposure with the drug solution. This opens more 
amorphous zones for drug molecules to diffuse into the tube 
matrix, hence extensive drug loss by diffusion into the tube 
matrix.
Drug uptake by the tube material was dependent on the 
total amount of drug exposed to the tube surface (Table 
VII). The amount of drug lost per square centimeter surface 
of the tube was dependent on the amount of drug exposed, 
that is, the volume of solution exposed. The total amount of 
drug lost from solution was greater for larger volumes of
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test solutions stored. For an adsorption process, an 
increase in surface area should result in an increase in the 
total amount of drug sorbed, and a constant amount of drug 
should be adsorbed to a constant surface area. In this 
study, the extent of drug loss increased as the amount of 
drug exposed increased, that is, more loss occurred with 
larger volumes present in the tube. While the percent of 
drug sorbed was about the same for each volume exposed, the 
amount of drug sorbed per square centimeter area increased 
with higher volumes. Therefore, the total amount of drug 
sorbed was independent of the surface area, but was 
dependent upon the total amount of drug exposed to the 
surface. This is consistent with drug diffusion or 
penetration into the solid matrix rather than drug 
adsorption onto the tube surface. The amount of drug 
adsorbed can be expected to be smaller than the amount 
absorbed because adsorption is a surface phenomena whereas 
absorption can involve interaction of the solute with the 
entire polymer matrix. Also adsorption should reach 
equilibrium quickly since, the binding sites on the tube 
surface can rapidly become saturated. A slow sorption 
equilibrium was observed in this study.
Drug loss in the tube variability studies (Tables XIII, 
IX, X and XI) showed larger variation in drug sorption among 
different Foley catheters with the same as well as different 
concentration drug solutions. Variability in drug sorption 
within the same Foley catheter is minimal. The chemical 
structure within the polymer family can differ with the 
changes in manufacturing conditions at different time 
periods, which leads to differences in properties. Inter 
tube variability might be caused by variation in the 
composition of the polymer, molecular weight distribution, 
crystallinity, cross-linking and additives among different 
batches. Crystalline regions are generally very resistant to 
penetrating molecules and molecules pass only through the 
amorphous regions. Because high molecular weight regions are
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highly crystalline, they have low permeability to drug 
molecules. Cross-linking may also decrease the swelling 
tendency of a plastic when in contact with a solvent having 
high affinity for the material, thus low permeability. 
Cross-linking stiffens the chains, therefore tightly cross- 
linked or stiff chained polymers retard diffusion.
Additives used in the tube manufacture might also alter 
the physicochemical properties of the polymers, producing 
variability in drug sorption. Leaching of additives into the 
solvent creates more lesions on the tube surface, which 
enhances drug sorption. Leaching was observed only from 
Foley catheters but not from Ross tubes. Leached substances 
from Foley catheters could be plasticizer, adhesives or 
other substances used to bind the teflon layer to the 
rubber. Leached substances could be toxic or incompatible 
with the drug. Tube variability in drug sorption was once 
again evident in the effect of pre-washing of tubes on drug 
loss studies (Table XIII).
Irreversible drug loss to delivery tubings was observed 
in the data in Table XII for desorption studies. Table XIV 
for the study of nature of drug loss in Foley catheters and 
Table XVII (experiment 2) in the Ross tube. As stated 
previously, it is possible that triazolam initially was 
adsorbed to the tube surface and slowly diffused into the 
tube matrix. Since there was no significant desorption of 
the sorbed drug, it indicates that the drug molecules were 
tightly bound to the tubing. Irreversible drug loss to the 
tubing might suggest that chemical binding was involved in 
the sorption process. However, since triazolam is 
predominantly non-ionized in aqueous solution, the most 
likely interactions would be either Van der Waals forces or 
weak dipole interactions. Poor water solubility and little 
or no hydrogen bonding capacity prevents desorption of the 
drug from the tube into the water. Irreversibility can also 
be explained by a higher affinity of the drug for plastic 
than water, therefore no recovery in water.
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The results observed for baclofen further strengthens 
the above interpretation. Baclofen has both basic and acidic 
groups in its structure and is mostly in the ionized form. 
Therefore it is polar and water soluble. In contrast to 
triazolam, these physicochemical properties did not favor 
the sorption of baclofen to the delivery tubes. In solution 
baclofen should have strong hydrogen bonding with the water 
molecules, that is why it is not partitioning into the tube 
material from aqueous solutions. In the baclofen studies, 
leaching of tube material did not show any effect on the 
delivery. A negative absorption was observed, that is, the 
baclofen concentration appeared to increase upon exposure of 
the solution to Foley catheters. Solvent absorption by the 
tubes would explain the observed increase in concentration 
of the drug.
Amount of drug required for monolayer coverage per 
square centimeter of the tube surface was calculated using 
the density value of 1.1 g/cm^ which is typical for 
chlorinated hydrocarbons. About 0.018 meg (see Appendix A) 
of triazolam can form a single layer per square centimeter 
of the tube surface. The observed drug loss per square 
centimeter of the tube surface was far greater than the 
calculated monolayer value. Therefore loss of drug is not 
mainly due to monolayer sorption but it could possibly be 
multilayer formation or chemisorption followed by diffusion 
into the tube matrix.
Sorption of drugs can be predicted if the fraction 
remaining in solution is known at 24 hours (109). Using the 
fraction remaining data sorption numbers can be calculated 
using the following equation.
Sn.t = 0.75[In Fj + 1/2f \  - 1/2]
If the drug loss is governed by diffusion control then the 
predicted drug loss should be close to the observed drug 
loss.
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Table XXIII; Sorption number calculation using fraction 
remaining data and calculation of predicted 
drug loss with the sorption number at 24 hours.
Time (hr) Sn/hour Drug
Predicted
loss
observed
0.5 0.12 12.5 23
1 0.06 17 23
2 0.03 23 24
4 0.02 30 25
8 0.01 38 27
12 0.01 43 33
24 0.03 52 52
Sn: Sorption number.
Results in table XXIII showed variation in observed and 
predicted drug loss at earlier and later times. Higher 
observed drug loss than predicted at half hour indicates 
that the initial rapid drug loss is not due to diffusion. 
Close estimates of drug loss between one and four hours 
indicates that initially the drug is lost rapidly due to 
adsorption followed by diffusion. Decrease in rate of 
sorption at higher times further supports the diffusion 
controlled sorption mechanism. The mechanisms described in 
the recent publication (109) cannot be applied directly to 
this study because of differences in volumes, surface area 
and plastics (polyvinylchloride versus teflon and 
polyurethane) and different drugs. Since there was large 
variability in drug sorption among different tubes it is 
difficult to calculate the exact sorption number for 
triazolam in the tubes studied.
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CONCLUSIONS
Delivery of triazolam and baclofen, two drugs commonly 
administered to critically ill patients by G-tubes, was 
studied in Foley catheters and Ross flexiflo tubes. 
Conclusions drawn from the observations and theoretical 
principles are:
Significant drug loss (20-70%) was observed for 
triazolam in both Foley catheters and Ross tubes in 24 hour 
sorption studies. Drug loss to tube materials could be 
related to the physicochemical properties of drug and tube 
materials. The slow equilibration was consistent with 
diffusion controlled penetration of the drug into the tube 
matrix. The large extent of drug loss was attributed to drug 
absorption into the matrix rather than adsorption to the 
tube surface. Concentration dependent drug loss was most 
consistent with absorption rather than adsorption, and was 
also consistent with drug penetration into the tube 
material. Persistent drug loss in repeated trials suggests 
diffusion of drug into the tube matrix, rather than a mono­
layer adsorption. The irreversibility of triazolam sorption 
is consistent with a process in which the lipophilic drug 
partitions into the non-polar matrix of the tubing but does 
not redistribute back to water. The observed rapid initial 
loss of drug from solution followed by a slow perpetual loss 
suggests a rapid adsorption of drug onto the tube surface 
may occur followed by slow time dependent diffusion into the 
tube matrix. In surface area studies, the extent of drug 
loss was dependent upon the amount of drug presented to the 
tube and not on the total surface area exposed. A greater 
amount of drug was lost as the ratio of amount of drug 
exposed to total surface area was increased. Surface area 
independent drug loss was consistent with solute diffusion 
into the tube matrix but not adsorption onto the tube 
surface. Variability in drug loss was observed among 
different Foley catheters with equal and different 
concentrations. Changes in the tube construction and
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physicochemical properties would explain the greater inter- 
tube variability than intra-tube variability in drug 
sorption. Tube materials from Foley catheters leached into 
the drug solution which was in contact with the tube. The 
leached materials were not identified but might be 
plasticizer, adhesives used to bind the teflon layer, or 
lubricants used in the tube manufacture. It is possible that 
the leached substances could be toxic and incompatible with 
the drugs.
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APPLICATION OF RESULTS
Sorption of a significant amount of triazolam to both 
Foley catheters and Ross flexiflo G-tubes indicates that 
this drug has potential delivery problems in these tubes. 
Triazolam sorbs to tubes because of its low water solubility 
and high affinity for lipids. Sorption could be reduced by 
increasing the water solubility of the drug. Water 
solubility of this compound can be increased by increasing 
the percent ionized. The pH where triazolam is mostly 
ionized is highly acidic and therefore is not practical in 
clinical use. Use of co-solvents could possibly increase the 
solubility of triazolam in solution, leading to a decrease 
in sorption. Drug loss was dependent on the concentration, 
the time, the amount of drug exposed, and the flow rate. 
Therefore, to minimize drug loss to the tubes, dilute 
solutions should be administered in less than 30 mins for 
intermittent and bolus administration. Results from this 
study suggest that a triazolam concentration of less than 10 
mcg/ml at a flow rate of 1 ml/min or greater would not have 
significant drug loss to either Foley catheter or Ross 
tubes.
Tubes should be washed with water after each dose to 
wash the residual drug from the tube surface. Drugs with low 
water solubility should not be administered with nutrient 
formulas because of the potential for interaction between 
food and drug or enhanced interaction of the drug with the 
tubes, due to a decrease in water solubility of the drug.
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Appendix A; Monolaver calculations for Triazolam 
Fluid density (d) of triazolam = 1.1 g/cm^
Radius of .
the molecule (r̂ ) = (3/4»rd) * 343 * (1/ (6.02 E23))
= 1.237 * 10 E-22 
r = 4.98 * 10 E-8
Area of .
the molecule = 47rr̂  .
= 3.12 * 10 E-14 cm^
nMass/cm^ for
monolayer coverage = f343 * fl/f6.02 * 10E-23n^
4ïrr̂
= 1.827 * 10 E^8 g/cm^
= 0.018 mcg/cm^
Appendix B: Statistics and Symbols used in Appendices 1-16 
Statistics:
A special case of anova is considered as a two 
sample t-test when there are only two groups. The t 
values can be obtained from the data tables by taking 
the square root of the F ratio value.
Symbols used:
aufs = absorption units full scale 
aup = area under peak 
n = number of observations 
c = control 
t = test
esd = standard deviation
■2measured values are lO*̂  * values shown 
(e.g 555 = 555,000)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD■ DOQ.Cg
Q .
■D
CD
Appendix 1; Sorption studies for Triazolam in Foley catheters
C/)Wo'30
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Q.Cao
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Exp. Tube
*
Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test
I
C
\
T
esd 
C T
Statistics 
F-Ratio Prob
1 I Tab (100) 100 0.2 555 353 2 5 17 11 358 <.0001
2 I Tab (100) 100 0.2 634 370 5 7 24 35 212 <.0001
I water 0 0.2 — 54 2 2 - -
4 I Tab (100) 100 0.2 847 319 4 2 19 2 1351 <.0001
5 I Tab (100) 100 0.2 694.5 424 4 2 33 15 222 <.0001
II 518 5 36
6 I Tab (100) 50 0.2 332 249 3 4 10 7 359 <.0001
II 100 634 415 5 5 24 10
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Appendix 2; Loss of Triazolam with respect to concentration in Foley catheter
Exp. Tube
#
Drug
source
Cone,
mcg/ml
AUFS Integrated AUP 
Control Test C
n
T
esd 
C T
Statistics 
F-Ratio Prob
1 la Tab (100) 100 0.2 528 199 5 , 5 20 6 783 <.0001
Ilb Tab (100) 50 222 101 3 3 8 8 555 <.0001
Ila Tab (100) 100 528 195 5 2 20 4
lib Tab (100) 50 222 78 3 4 8 2
2 Ic Tab (25) 25 0.02 3829 1559 6 3 113 97 285 <.0001
Id Tab (25) 10 1510 1185 5 2 40 124 81 <.0001
lie Tab (25) 25 3829 2544 6 3 113 211
Ild Tab (25) 10 1510 918 5 3 40 60
3 Ilia Tab (25) 25 0.02 3561 1916 4 4 17 78 297 <.0001m b Tab (25) 10 1453 790 2 4 74 47 144 <.0001
IIIc Tab (25) 25 3561 2082 4 3 17 182
Illd Tab (25) 10 1453 869 2 3 74 21
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Appendix 4; Loss of Triazolam with respect to surface area in Foley catheter
C/)(ho'3O
8
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Exp
/
Tube Drug
source
Cone.
mcg/ml AUFS
Integ. 
Control
AUP
Test C
n
T
esd 
C T
Statistics 
F-Ratio Prob
1 A (3 ml) Tab (25) 25 0.02 3382 3050 6 4 56 103 30 <.0001
B (2 ml) 2997 5 60
C (1 ml) 2991 5 104
2 A (3 ml) Tab (100) 100 0.1 1161 1045 4 3 20 10 201 <.0001
B (2 ml) 971 3 10
C (1 ml) 849 2 19
3 A (3 ml) Tab (25) 25 0.02 3405 3159 4 3 58 31 23 <.0001
B (2 ml) 3423 4 52
C (1 ml) 3203 3 61
4 D (3 ml) Tab (25) 25 0.02 2287 2080 6 5 17 54 79 <.0001
E (2 ml) unstirred 1985 4 35
F (1 ml) 2015 5 36
5 D (3 ml) Tab (25) 25 0.02 2424 2143 2 5 0.7 53 54 <.0001
E (2 ml) unstirred 2141 5 29
F (1 ml) 4050 5 20
6 D (3 ml) Tab (25) 25 0.02 2748 2345 4 5 36 65 58 <.0001
E (2 ml) 2355 5 69
F (1 ml) 2311 5 42
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Appendix 5; Equilibrium study of Triazolam in Foley catheter
Exp.
#
Tube
#
Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd 
C T
Statistics 
F-Ratio Prob
1 la Tab (25) 25 0.02 3793 2807 5 2 25 20 2681 <.0001
Ib 2759 3 55
Ic 1661 2 22
Id 1444 3 36
2 Ila Tab (25) 25 0.02 3793 2766 5 3 25 84 1501 <.0001
lib 2828 2 10
lie 1848 3 32
lid 1813 3 15
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Appendix 6: Equilibrium study of Triazolam in Foley catheter
Exp.
#
Tube
#
Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd
C T
Statistics 
F-Ratio Prob
1 luv Tab (25) 25 0.02 3860 3360 4 3 45 113
Iw 3398 2 48
2 luw 3576 2 19
IW 3686 2 78
3 luw 3752 2 59
Iw 3538 3 81
4 luw 3668 2 17
Iw 3700 2 ' 23
5 luw Tab (25) 25 0.02 3793 3717 5 2 25 62
Iw 3576 2 9
6 luw Tab (25) 25 0.02 3838 3499 3 2 108 18
Iw 3485 2 119
7 luw 3730 2 4
flw 3442 2 36
8 luw 3688 2 8
Iw 3532 2 77
9 luw 3545 2 82
Iw 3506 2 134
10 luw 3386 2 69
Iw 3465 2 30
CD■ DOQ.CgQ.
■D
CD
C/)Wo"3O
8
ci'
Appendix 7: Effect of pre-washing on Triazolam sorption
Exp. Tube Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd 
C T
Statistics 
F-Ratio Prob
1 la Tab (100) 100 0.1 1064 314 5 2 50 9 194 <.0001
Ib Tab (100) 100 389 2 6
Ic Tab (100) 100 580 2 33
Id Tab (100) 100 444 3 48
2 Ila Tab (100) 100 0.1 1065 262 5 2 50 23 300 <.0001
lib Tab (100) 100 447 2 28
lie Tab (100) 100 397 4 23
lid Tab (100) 100 472 2 13
3 Ilia Tab (25) 25 0.02 3635 2783 5 3 55 55 173 <.0001
Illb Tab (25) 25 2980 4 91
IVa Tab (25) 25 0.02 2562 3 36 561 <.0001
IVb Tab (25) 25 2627 3 42
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Appendix 8; Clinical simulation study of Triazolam in Foley catheter
Exp. Tube Drug Cone. Integrated AUP n esd Statistics 1# source mcg/ml AUFS Control Test C T C T F-Ratio Prob
I I Tab (25) 25 0.02 3451 3467 3 4 15 51 2805 619
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Appendix 9: Sorption studies for Triazolam in Ross tube
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Exp.
/
Tube Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd
C T
Statistics 
F-Ratio Prob
1 I Tab (25) 25 0.02 3793 1051 5 4 25 29 24048 <.0001
2 I water — — 0.02 — — 307.7 3 0.6
3 I Tab (25) 25 0.02 3793 1325 5 4 25 28 19784 <.0001
4 I Tab (12.5) 12.5 0.02 2021 1150 3 3 46 26 820 <.0001
5 I Tab (12.5) 12.5 0.02 1981 1287 3 3 86 35 168 . 0002
6 I Tab (25) 25 0.02 3860 1876 4 3 45 69 2134 <.0001
7 I Tab (12.5) 12.5 0.02 1936 1362 3 3 78 35 186 .0003
8 I Tab (12.5) 12.5 0.02 1936 1359 3 3 54 98 <.0001
9 I Tab (25) 25 0.02 3860 2040 4 3 45 57 2232 <.0001
10 I Tab (25) 25 0.02 3860 1484 4 3 48 4449 <.0001
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Appendix 10; Clinical simulation study of Triazolam in Ross tube
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Exp.
#
Tube
#
Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd 
C T
Statistics 
F-Ratio Prob
1 II Tab (25) 
(Ud)
25 0.02 1927 1776 5 4 35 57 24 .0017
2 II Tab (25) 25 0.02 3860 3898 4 3 45 66 0.86 .3962
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Appendix 11; Sorption study for Baclofen in Foley catheter
Exp. Tube
#
Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd 
C T
Statistics 
F-Ratio Prob
1 I tab 1000 0.2 2604 2595 4 4 72 40 0.03 0.97Ila tab 1000 0.2 2604 4 72Ilb 8 td 1000 0.2 2698 2630 4 3 43 45 4.2 0.097
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CD Appendix 12: Sorption study for Baclofen in Ross tube
C/)Wo'30
3
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Exp. Tube Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test
n
■ C T
esd 
C T
Statistics 
F-Ratio Prob
1 I tab 1000 0.2 2604 2697 4 3 72 11 4.76 0.0832
Appendix 13: Clinical simulation study for Baclofen in Foley catheter
3 "CD
CD■DO
Exp.
0
Tube Drug
source
Cone.
mcg/ml AUFS
Integrated AUP 
Control Test C
n
T
esd 
C T
Statistics 
F-Ratio ProbQ.C
ao 1 III tab 1000 0.2 2604 2622 4 3 72 28 0.16 0.703■DO3"CT
IV std 1000 0.2 2698 2723 4 3 43 25 0.557 0.497
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Clinical simulation Study for Baclofen in Ross tube
3
C/)
C/) Exp. Tube Drug Cone. Integrated AUP n esd Statisticso'
3 * # source mcg/ml AUFS Control Test C T C T F-Ratio Prob
1 II tab 1000 0.2 2604 2653 4 3 72 34 1.12 0.337
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